TABLE 2

Directional flux of dabrafenib in MDCKII-WT and MDCKII-MDR1 cells

Data represent the mean ± S.D. (n = 3).

Cell LinePappERCFR
A-to-BB-to-A
cm/s ×10−6cm/s ×10−6
MDCKII-WT2.6 ± 1.07.7 ± 1.63.0
MDCKII-WT + 1 μM LY3359795.5 ± 0.45.2 ± 0.70.90
MDCKII-MDR10.7 ± 0.3a7.9 ± 1.911.43.8
MDCKII-MDR1 + 1 μM LY3359794.9 ± 0.52b5.2 ± 1.41.1
  • A, apical; B, basolateral; CFR, corrected efflux ratio; ER, efflux ratio; MDCKII, Madin-Darby canine kidney II; Papp, apparent permeability of dabrafenib; WT, wild type.

  • a Significantly different compared with respective wild-type control cells.

  • b Significantly different compared with untreated MDR1 control cells.